Gefitinib, Erlotinib or Afatinib for EGFR Mutated NSCLC patients? A Meta-Analysis and Indirect Comparison on the Efficacy of First-Line Tyrosine Kinase Inhibitors
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2105
https://www.valueinhealthjournal.com/article/S1098-3015(16)33471-4/fulltext
Title :
Gefitinib, Erlotinib or Afatinib for EGFR Mutated NSCLC patients? A Meta-Analysis and Indirect Comparison on the Efficacy of First-Line Tyrosine Kinase Inhibitors
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33471-4&doi=10.1016/j.jval.2016.09.2105
First page :
A714
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1994